Integra Lifesciences Holdings (IART) EV to EBITDA (2009 - 2026)

Integra Lifesciences Holdings has disclosed EV to EBITDA across 18 years of filings, most recently posting 58.22 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 4349.35% year-over-year to 58.22; the TTM figure through Jun 2026 stood at 17.13 (up 1320.85% YoY), while the FY2025 annual figure was 1.43, down 102.74% from the prior year.
• EV to EBITDA came in at 58.22 for Q2 2026 at Integra Lifesciences Holdings, up from 40.74 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 537.42 in Q1 2024 to a low of 648.33 in Q2 2024.
• Average EV to EBITDA over 5 years is 40.78, with a median of 59.48 recorded in 2026.
• Year-over-year, EV to EBITDA slumped 366.76% in 2024 and jumped 4349.35% in 2026.
• Over 5 years, EV to EBITDA stood at 60.74 in 2022, then surged by 41.46% to 85.93 in 2023, then plunged by 51.73% to 41.48 in 2024, then decreased by 26.31% to 30.57 in 2025, then jumped by 90.46% to 58.22 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 58.22 in Q2 2026, 40.74 in Q1 2026, and 30.57 in Q4 2025.